<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-601
Date of Submission: 2025-04-02

This report was submitted by a Other Healthcare Professional from Pena and Sons Medical Center concerning patient ANON-PX-7544. The subject is an adult other with a significant medical history including type 2 diabetes, coronary artery disease, chronic kidney disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Subcutaneous route at a dosage of 218mg, initiated on 2025-01-04 for Neuropathic pain and discontinued on 2025-02-08; Warfarin administered via the Intravenous route at a dosage of 490mg, initiated on 2025-01-04 for Thromboembolism prevention and discontinued on 2025-02-08.

On approximately 2025-02-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Pruritus. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: My by stock civil. Hundred claim factor not head employee. Shoulder at beat include seem Mrs. Bad do and boy upon occur.</data>
report_id: ADR-2025-601
report_date: '2025-04-02'
patient_details:
  patient_id: ANON-PX-7544
  gender: Other
  relevant_history:
  - type 2 diabetes
  - coronary artery disease
  - chronic kidney disease
  - hypertension
suspected_drugs:
- drug_name: Gabapentin
  dosage: 218mg
  route_of_administration: Subcutaneous
  start_date: '2025-01-04'
  indication_for_use: Neuropathic pain
  end_date: '2025-02-08'
- drug_name: Warfarin
  dosage: 490mg
  route_of_administration: Intravenous
  start_date: '2025-01-04'
  indication_for_use: Thromboembolism prevention
  end_date: '2025-02-08'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-02-06'
  severity: Severe
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2025-02-06'
  severity: Mild
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 4
reporting_facility: Pena and Sons Medical Center
reporter_type: Other Healthcare Professional
notes: My by stock civil. Hundred claim factor not head employee. Shoulder at beat
  include seem Mrs. Bad do and boy upon occur.
